论文部分内容阅读
目的观察造血干细胞移植(HSCT)患者出现真菌感染的临床特点,并探讨伊曲康唑抗真菌感染的疗效。方法对该院2008年1月至2010年10月334例接受HSCT术治疗的病例真菌感染的临床治疗情况进行回顾性分析。90例HSCT患者术后被诊断为真菌感染,全部病例均予静脉注射伊曲康唑治疗,125~250毫克/次,第1、2天给予2次/天,第3天后给予1次/天,病情稳定后改为伊曲康唑口服液治疗。结果 HSCT患者术后真菌感染的发生率为27%,接受伊曲康唑治疗的患者有效率75.6%。确诊患者中10例(76.9%)有效,临床诊断病例58例(75.3%)有效。结论 HSCT患者术后真菌感染发病率高;伊曲康唑疗效明确,可用于HSCT患者术后患者抗真菌感染的治疗。
Objective To observe the clinical features of fungal infection in patients with hematopoietic stem cell transplantation (HSCT) and to evaluate the efficacy of itraconazole in antifungal infection. Methods A retrospective analysis was performed on the clinical treatment of fungal infections in 334 cases undergoing HSCT in our hospital from January 2008 to October 2010. 90 cases of HSCT patients were diagnosed as fungal infection after surgery, all cases were given intravenous itraconazole treatment, 125 to 250 mg / time on the 1st and 2nd days to give 2 times / day, after the first 3 days to give 1 / day , Stable condition changed to Itraconazole oral solution. Results The incidence of postoperative fungal infection was 27% in HSCT patients and 75.6% in patients receiving itraconazole. Of the 10 diagnosed patients (76.9%) were effective, 58 cases (75.3%) were clinically diagnosed. Conclusion The incidence of postoperative fungal infection in HSCT patients is high. Itraconazole has a definite effect and can be used in the treatment of postoperative patients with HSCT.